S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
Log in
NASDAQ:NEOS

Neos Therapeutics Stock Forecast, Price & News

$0.97
+0.08 (+8.98 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.90
Now: $0.97
$0.98
50-Day Range
$0.70
MA: $0.89
$1.26
52-Week Range
$0.45
Now: $0.97
$1.62
Volume2.14 million shs
Average Volume5.44 million shs
Market Capitalization$48.33 million
P/E RatioN/A
Dividend YieldN/A
Beta1.5
Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.
Neos Therapeutics logo

Headlines

NEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER...
December 16, 2020 |  benzinga.com
Is NEOS A Good Stock To Buy Now?
December 7, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NEOS
CUSIPN/A
Phone972-408-1300
Employees213
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$64.65 million
Book Value($0.12) per share

Profitability

Net Income$-16,900,000.00

Miscellaneous

Market Cap$48.33 million
Next Earnings Date3/12/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

0.75 out of 5 stars

Medical Sector

1183rd out of 1,958 stocks

Pharmaceutical Preparations Industry

540th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$0.97
+0.08 (+8.98 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NEOS News and Ratings via Email

Sign-up to receive the latest news and ratings for NEOS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Neos Therapeutics (NASDAQ:NEOS) Frequently Asked Questions

Is Neos Therapeutics a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neos Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Neos Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NEOS, but not buy additional shares or sell existing shares.
View analyst ratings for Neos Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Neos Therapeutics?

Wall Street analysts have given Neos Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Neos Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Neos Therapeutics?

Neos Therapeutics saw a decrease in short interest in January. As of January 29th, there was short interest totaling 995,500 shares, a decrease of 34.5% from the January 14th total of 1,520,000 shares. Based on an average trading volume of 5,610,000 shares, the short-interest ratio is presently 0.2 days. Approximately 2.1% of the shares of the company are short sold.
View Neos Therapeutics' Short Interest
.

When is Neos Therapeutics' next earnings date?

Neos Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for Neos Therapeutics
.

How were Neos Therapeutics' earnings last quarter?

Neos Therapeutics, Inc. (NASDAQ:NEOS) posted its quarterly earnings results on Monday, November, 9th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.05. The company earned $12.54 million during the quarter.
View Neos Therapeutics' earnings history
.

How has Neos Therapeutics' stock been impacted by COVID-19?

Neos Therapeutics' stock was trading at $1.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NEOS shares have decreased by 29.6% and is now trading at $0.9713.
View which stocks have been most impacted by COVID-19
.

Who are Neos Therapeutics' key executives?

Neos Therapeutics' management team includes the following people:
  • Mr. Gerald W. McLaughlin, CEO, Pres & Director (Age 53, Pay $561.95k)
  • Mr. Richard I. Eisenstadt, CFO, Treasurer & Corp. Sec. (Age 63, Pay $387.59k)
  • Ms. Margaret Cabano, VP of Operations
  • Mr. John P. Limongelli, Sr. VP, Gen. Counsel & Corp. Sec. (Age 51)
  • Mr. Joe Calarco, Chief Compliance Officer
  • Ms. Sarah Foster, VP of HR
  • Mr. Russ McMahen, Sr. VP of R&D

What is Mark Tengler's approval rating as Neos Therapeutics' CEO?

10 employees have rated Neos Therapeutics CEO Mark Tengler on Glassdoor.com. Mark Tengler has an approval rating of 26% among Neos Therapeutics' employees. This puts Mark Tengler in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Neos Therapeutics' key competitors?

What other stocks do shareholders of Neos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neos Therapeutics investors own include Verastem (VSTM), SCYNEXIS (SCYX), TherapeuticsMD (TXMD), TG Therapeutics (TGTX), AcelRx Pharmaceuticals (ACRX), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL), Progenics Pharmaceuticals (PGNX), T2 Biosystems (TTOO) and Agile Therapeutics (AGRX).

When did Neos Therapeutics IPO?

(NEOS) raised $60 million in an initial public offering on Thursday, July 23rd 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

What is Neos Therapeutics' stock symbol?

Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."

Who are Neos Therapeutics' major shareholders?

Neos Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (9.97%), Renaissance Technologies LLC (2.16%) and Virtu Financial LLC (0.08%).
View institutional ownership trends for Neos Therapeutics
.

Which major investors are buying Neos Therapeutics stock?

NEOS stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Renaissance Technologies LLC, and Virtu Financial LLC.
View insider buying and selling activity for Neos Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Neos Therapeutics?

Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neos Therapeutics' stock price today?

One share of NEOS stock can currently be purchased for approximately $0.97.

How much money does Neos Therapeutics make?

Neos Therapeutics has a market capitalization of $48.33 million and generates $64.65 million in revenue each year. The company earns $-16,900,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

How many employees does Neos Therapeutics have?

Neos Therapeutics employs 213 workers across the globe.

What is Neos Therapeutics' official website?

The official website for Neos Therapeutics is www.neostx.com.

Where are Neos Therapeutics' headquarters?

Neos Therapeutics is headquartered at 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050.

How can I contact Neos Therapeutics?

Neos Therapeutics' mailing address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]


This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.